Efficacy of Response-adapted Treatment in Patients With Multiple Myeloma Candidates for Bone Marrow Transplantation
Multiple Myeloma
About this trial
This is an interventional treatment trial for Multiple Myeloma focused on measuring Minimal Residual Disease, Therapeutics, Multiple Myeloma
Eligibility Criteria
Inclusion Criteria: Younger than 76 years Diagnosed with Multiple Myeloma from July 1, 2014 to May 31, 2019 Received some of the standard authorized treatments for their therapeutic line. Patients treated in clinical trials with treatments not yet authorized, for fifth or successive therapeutic lines are admitted. Give informed consent Fit patient Exclusion Criteria: Under 18 years old Contraindication for bone marrow auto-transplantation Therapeutic objective only palliative: Another non-treatable neoplasm Severe senile dementia Significant comorbidity limiting life expectancy to less than 6 months
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Experimental
No Intervention
MRDI-driven treatment
Conventional treatment
Patients continue treatment until complete remission with negative MRD and Image is achieved, changing the therapeutic line if this is not achieved with the prescribed treatment. In this group of patients, treatment is suspended only when this degree of profound response is reached, in any phase of treatment.
The patients of the conventional treatment group (control group) received six cycles of the induction traetment, bone marrow auto-transplantation, and consolidation treatment after transplantation if complete remission had not been achieved.